Fasenra Purple Book BLA 761070

BLA number
761070
Proprietary names
Fasenra
Proper names
benralizumab
Applicant
AstraZeneca AB
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Fasenrabenralizumab351(a)30MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2017-11-14
002Fasenrabenralizumab351(a)30MG/MLInjectionSubcutaneousAutoinjectorRxLicensed2019-10-03
003Fasenrabenralizumab351(a)10MG/0.5MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2024-04-05

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-11-01U001Fasenra351(a)RxAstraZeneca AB
2024-11-01U002Fasenra351(a)RxAstraZeneca AB
2024-11-01U003Fasenra351(a)RxAstraZeneca AB
2024-04-01N003Fasenra351(a)RxAstraZeneca AB
2020-05-01R001Fasenra351(a)RxAstraZeneca AB
2020-05-01R002Fasenra351(a)RxAstraZeneca AB

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2024-04-01003Fasenra351(a)RxLicensed2024-04-05
2020-05-01001Fasenra351(a)RxLicensed2017-11-14
2020-05-01002Fasenra351(a)RxLicensed2019-10-03